CD274 and neoplasm: The ICB-naïve patient had a PD-L1-low tumor and had received prior HPV16 E7 T cell receptor (TCR) gene engineered T-cell therapy following standard-of-care treatment with chemotherapy and bevacizumab for cervical cancer.